NewsEuropeGerman Medical Cannabis Scripts Mainly For Pain

German Medical Cannabis Scripts Mainly For Pain

-

PAIN is most common ailment for which patients are prescribed medical cannabis, say the German Government 

The introduction of its medical cannabis programme in 2017 saw physicians allowed to prescribe medicinal cannabis for over 60 illnesses.

Almost three quarters of all prescriptions from a Government sample of over 6,500 are for pain – at 71%

This was followed by spasticity – a muscle condition at 11% – and anorexia at 7%, with epilepsy,  migraines, ADHD and Tourettes Syndrome all featuring, too.

The data is based on an ongoing government survey involving 6,538 patients, as of September last year, reports the Marijuana Business Daily website.

This survey on the medical market will run until March 2022 and will then be used determine the future of medical cannabis insurance coverage.

Germany’s medical cannabis programme began in March 2017, and 

‘The Germany Cannabis Report’  by  Prohibition Partners  estimates 60,000 patients have been helped.

One of the most pressing issues in the German market is that it does not have the supply chain to satiate demand and has consequently granted supply licenses to three Canadian, and one domestic, producer while it  encourages the development of a homegrown industry.

This comes an estimated four million Germans use cannabis, with 17% of 18 to 25-year-olds saying they had used it in the past 12 months.

Despite being illegal, the state will not usually prosecute anyone found to have six grams of cannabis, or less – a limit agreed by state interior ministers, in 2018.

https://mjbizdaily.com/new-data-reveals-to

Peter
Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

British People Open To Using Medical Cannabis – Yet Majority Unaware They Can Access It On Prescription 

A NEW national survey of 4,000 people has highlighted the need to improve awareness of cannabis as a medicine.  Key...

As US Hemp Cultivation Levels Plummet The Established European Industry Continues To Flourish 

DESPITE a huge decline in US hemp industry’s footprint the European industry will continue to grow, say the continent’s...

Chrystal Capital Acts As Exclusive Advisor To Change Agronomy On £9.6m Fundraise

CHRYSTAL Capital Partners LLP, is an entrepreneurial corporate finance and investment house with an established global network of Single...

European Cannabis Stocks Review: ‘End’ Of US Cannabis Bear Market Rallies European Stocks 

FOLLOWING last week’s rally there has seen something of a lull with little movement for European cannabis stocks. Last week’s...

Business of Cannabis Conference Returns to New York City on November 3rd

In this second summit, the most influential business leaders, investors and politicians gather to discuss social equity, policy and...

Curaleaf Takes Majority Stake And Forms Strategic Partnership With Germany’s Four 20 Pharma In €20m Deal

CURALEAF Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), a leading U.S. provider of consumer products in cannabis, announced that Curaleaf International...

Must read

As US Hemp Cultivation Levels Plummet The Established European Industry Continues To Flourish 

DESPITE a huge decline in US hemp industry’s footprint...

European Cannabis Stocks Review: ‘End’ Of US Cannabis Bear Market Rallies European Stocks 

FOLLOWING last week’s rally there has seen something of...

You might also likeRELATED
Recommended to you